 Home > Medical News > Latest Medical News > Qinhao Pharmaceutical obtained the first IND approval in China

Qinhao Pharmaceutical obtained the first IND approval in China

 Last Update: 2021-06-22
 Source: Internet
 Author: User

Tags

msn drug

cardene drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China shows that Gen House's Class 1 new drug GH35 tablets have obtained two clinical trials implied approval, and the indication is advanced solid tumors

Screenshot source: CDE official website

According to the press release of Qin Hao Pharmaceutical, GH35 is a KRAS G12C inhibitor under development.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.